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Introduction: Computed tomography (CT) plays a central role in 
lung cancer diagnosis. However, CT has relatively low specificity, 
presenting a challenge in clinical settings. We previously identified 
12 microRNAs (miRNAs) whose expressions in tumor tissues were 
associated with lung cancer.
Methods: Using quantitative reverse transcriptase polymerase chain 
reaction, we aimed to identify miRNA biomarkers in sputum that 
could complement CT for diagnosis of lung cancer.
Results: In a training set consisting of 66 lung cancer patients and 
68 cancer-free smokers, 10 of the 12 miRNAs were differentially 
expressed between the cases and controls (p ≤ 0.01). From the miR-
NAs, a logistic regression model was built on the basis of miR-31 
and miR-210, both of which had the best prediction for lung cancer, 
producing an area under receiver operating characteristic curve of 
0.83. Combined use of the two miRNAs yielded 65.2% sensitivity 
and 89.7% specificity, CT had 93.9% sensitivity and 83.8% speci-
ficity for lung cancer diagnosis. Notably, combined analysis of the 
miRNA biomarkers and CT produced a higher specificity than does 
CT used alone (91.2% versus 83.8%; p < 0.05). The diagnostic per-
formance of the biomarkers was confirmed in a testing set compris-
ing 64 lung cancer patients and 73 cancer-free smokers.
Conclusion: The sputum miRNA biomarkers might be useful in 
improving CT for diagnosis of lung cancer, but further independent 
validation on an external and prospective cohort of patients is required.
Key Words: Lung cancer, MicroRNAs, Sputum, Computed tomog-
raphy, Diagnosis.
(J Thorac Oncol. 2014;9: 33–40)
Lung cancer is the second most common cancer and the number one cancer killer in the United States and world-
wide.1 Lung cancer is classified into non–small-cell lung can-
cer (NSCLC) and small-cell lung carcinoma (SCLC).2 NSCLC 
accounts for approximately 80%, whereas SCLC comprises 
about 20% of all lung cancers. NSCLC is further divided into 
two main subtypes: adenocarcinoma (AC) and squamous-
cell carcinoma (SCC).3,4 The 5-year survival rate for stage IV 
NSCLC is only 10%, whereas it is approximately 80% for stage 
IA NSCLC.5 Furthermore, the median survival of limited-stage 
SCLC with treatment is 18 to 24 months. The median survival 
of extensive-stage SCLC is 6 to 12 months with treatment, and 
only 2 to 4 months without treatment.6 These statistics provide 
the primary rationale to improve the early detection of lung can-
cer.5,7 Chest radiograph has been used for early detection of lung 
cancer, yet the sensitivity is low.5 A National Cancer Institute–
National Lung Screening Trail recently found 20% fewer lung 
cancer deaths in smokers among those who were screened with 
computed tomography (CT) compared with those who were 
screened with chest radiograph.8 Therefore, American Cancer 
Society recently recommends low-dose CT screening for lung 
cancer for individuals who are 55 to 74 years old, have at least 
a 30-pack-year smoking history, and currently smokes or have 
quit within the past 15 years. However, the results of National 
Lung Screening Trail show that CT screening has only 61% 
specificity for lung cancer diagnosis.8 The low specificity often 
results in anxiety, unnecessary biopsies, and surgeries that carry 
their own risks to many smokers who have benign diseases. 
There is, therefore, an urgent need to develop noninvasive and 
cost-effective approaches that can augment CT, particularly 
increase its specificity, for diagnosis of lung cancer.
Sputum is one of the most easily and noninvasively 
accessible body fluids.9–11 Sputum contains airway epithelial 
cells. Analysis of sputum can indicate the specific source of 
the abnormal airway epithelial cells in the lungs, thus pro-
viding an organ-specific approach for lung cancer diagnosis. 
Cytological analysis of sputum has been used for diagnosis 
of lung cancer.11 Yet the sensitivity is low.11 Molecular study 
of sputum has been used to identify neoplastic cells from 
lung cancer patients.12 For example, P16 hypermethylation 
was found in sputum collected from patients with lung can-
cer 5 to 35 months before cytological and clinical diagnoses 
of NSCLC.13,14 The assessment of chromosomal aneusomy in 
exfoliated cells of sputum could help diagnose lung cancer 
with 76% sensitivity and 88% specificity.15,16 We have previ-
ously shown that a panel of sputum-based DNA probes has a 
higher sensitivity for diagnosis of NSCLC patients than does 
conventional sputum cytology.17,18
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MicroRNAs (miRNAs) are a class of naturally occurring, 
small noncoding RNA molecules, about 21 to 25 nucleotides 
in length.19,20 The small molecules play important functions in 
diverse biological processes, including cell proliferation, dif-
ferentiation, and apoptosis.19–21 miRNAs can transcriptionally 
regulate expressions of more than 30% of human protein-cod-
ing genes.19,20 Furthermore, some miRNAs act as oncogenes 
or tumor suppressors in tumorigenesis,22 and dysfunction of 
the miRNAs contributes to the development and progression 
of human malignancies, including lung cancer.22 For instance, 
we showed that miR-486-5p acted as a tumor suppressor in the 
progression and metastasis of lung cancer.23 Analyzing miR-
NAs in clinical specimens might provide a potential assay for 
diagnosis of lung cancer.21 Previously, we found that endog-
enous miRNAs were stably present in sputum and robustly 
measurable by using quantitative reverse transcription–poly-
merase chain reaction (qRT-PCR).24 Using a TaqMan-based 
miRNA array to profile 377 human mature miRNAs in 20 lung 
AC tissues and the matched normal lung tissues, we identified 
seven miRNAs that statistically differently expressed between 
the paired tumor and normal samples.25 These included four 
miRNAs (miR-21, miR-182, miR-31, and miR-200b) that 
were overexpressed and three miRNAs (miR-486, miR-126, 
and miR-375) that were underexpressed in tumor specimens.25 
Furthermore, using GeneChipR miRNA Arrays to profile 
expression signatures of 818 human mature miRNAs on 15 
lung SCC tissues and the paired normal lung tissues, we iden-
tified six miRNAs that were statistically differently expressed 
between the paired tumor and normal samples (all p < 0.01).26 
These included three miRNAs (miR-205, miR-210, and miR-
708) that were overexpressed, and three miRNAs (miR-126, 
miR-139, and miR-429) that were underexpressed in tumor 
specimens. In total, our studies25,26 identified 12 miRNA sig-
natures (miRs-21, 31, 126, 139, 182, 200b, 205, 210, 375, 
429, 486, and 708) whose aberrant expressions were associ-
ated with NSCLC. We further showed that analysis of four 
miRNAs (miR-21, miR-486, miR-375, and miR-200b) and 
three miRNAs (miR-205, miR-210, and miR-708) in sputum 
could diagnose lung AC and SCC, respectively, with higher 
sensitivities than sputum cytology could.25,26
On the basis of our previous studies,24–26 the objective 
of the present study was to determine whether analysis of the 
miRNA signatures could improve regular CT scan for diag-
nosis of lung cancer. From the 12 miRNAs, a panel of two 
miRNAs was identified, which could diagnose lung cancer 
covering major histological types with 65.2% sensitivity and 
89.7% specificity. Importantly, combined use of the miRNA 
biomarkers and CT provided a higher specificity than did CT 
used alone for lung cancer diagnosis.
PATIENTS AND METHODS
Patients and Sputum Samples
The study protocol was approved by the Institutional 
Review Boards of the University of Maryland Medical Center 
and Baltimore VA Medical Center. Sixty-six lung cancer 
patients and 68 cancer-free smokers were recruited from the 
University of Maryland Medical Center for a training set 
(Table 1), whereas 64 lung cancer patients and 73 cancer-free 
control smokers from Baltimore VA Medical Center were 
enrolled for a testing set (Table 2). The sputum samples were 
collected before the patients received surgical treatment, pre-
operative adjuvant chemotherapy and radiotherapy as previ-
ously described.24–26 In brief, subjects used water or saline to 
gently brush tongue, buccal surfaces, teeth, and gingival to 
remove superficial epithelial cells and bacteria, followed by 
gargling and rinsing with tap water. They were asked to spon-
taneously cough sputum as previously described.18,27–29 If this 
TABLE 1.  Demographic and Clinical Data of Lung Cancer Patients and Cancer-Free Controls in a Training Set
Parameter Lung Cancer Patients % Cancer-Free Controls %
Total No. 66 68
Age, yr, median (SD) 64 (7) 67 (5)
Sex
  Men 37 56.1 43 63.2
  Women 29 43.9 25 36.8
Race
  White American 38 57.6 48 70.6
  African American 28 42.4 20 29.4
Smoking, pack-years (SD) 53 (19) 49 (15)
Nodule size (cm), median (SD) 2.6 (1.1) 1.1 (0.7)
Histology
  Adenocarcinoma 27 40.9
  Squamous-cell carcinoma 26 39.4
  Small-cell carcinoma 13 19.7
Stage of 53 NSCLC
  I 17 32.1
  II 18 34.0
  III–IV 18 33.9   
NSCLC, non–small-cell lung cancer.
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was unsuccessful, participants underwent sputum induction. A 
variation of the ultrasonic nebulization technique described by 
Saccomanno9,10 was used for sputum induction. Participants 
inhaled a nebulized 3% saline solution from an ultrasonic neb-
ulizer for 20 minutes. Sputum was collected in a sterile speci-
men cup and centrifuged at 1000 g for 15 minutes. Cytospin 
slides were prepared from each sample and Papanicolaou 
staining was performed on these to evaluate whether sputum 
was representative of deep bronchial cells. To ensure the qual-
ity of the sputum, the spontaneous or induced sputum samples 
that had less than 4% oral squamous cells were considered to 
be adequate for the present study. The cell pellet from each 
sample was then resuspended in Sputolysin (Calbiochem, 
San Diego, CA) for 15 minutes at 37°C. The cell pellet was 
washed again and stored at −80°C for molecular analysis. 
Presence of solitary pulmonary nodules (SPNs) in the cases 
and controls was determined based on chest CT scan. Final 
diagnosis for lung cancer was made with histopathologic 
examinations of specimens obtained by CT-guided transtho-
racic needle biopsy, transbronchial biopsy, videotape-assisted 
thoracoscopic surgery, or surgical resection. The surgical 
pathologic staging was determined according to the tumor, 
node, metastasis (TNM) classification of the International 
Union Against Cancer with the American Joint Committee on 
Cancer and the International Staging System for Lung Cancer. 
Histopathological classification was determined according to 
the World Health Organization classification. The cancer-free 
smokers had no cancer diagnoses in the last 3 years.
RNA Isolation and Expression 
Analysis of miRNAs by qRT-PCR
Total RNA containing small RNA was extracted from cell 
pellets of the sputum specimens as previously described.24–26,30 
The purity and concentration of RNA were determined from 
OD260/280 readings by using a dual-beam Ultraviolet (UV) 
spectrophotometer (Eppendorf AG, Hamburg, Germany). 
RNA integrity was determined by capillary electrophore-
sis by using the RNA 6000 Nano Lab-on-a-Chip kit and the 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). 
Twelve miRNAs (miRs-21, 31, 126, 139, 182, 200b, 205, 210, 
375, 429, 486, and 708) were evaluated in sputum by using 
qRT-PCR with Taqman miRNA assays (Applied Biosystems, 
Foster City, CA) as previously described.24–26 Briefly, RNA was 
applied for reverse transcription (RT) by using the Applied 
Biosystems 9700 Thermocycler (Applied Biosystems) with 
miRNA-specific looped primer and TaqMan MicroRNA RT 
Kit (Applied Biosystems), according to the manufacturer’s 
instructions. The reaction includes 50 nM stem-loop RT 
primer, ×1 RT buffer, 0.25 mM each of deoxyrinonucleotides, 
and 3.33 U/μl MultiScribe reverse transcriptase in a total vol-
ume of 15 μl. The 20 μl PCR reaction included RT product, 
×1 TaqMan Universal PCR Master Mix (Applied Biosystems), 
and the corresponding primers and Taqman probe for the target 
genes. The reactions were incubated in a 94-well plate at 95°C 
for 15 minutes, followed by 45 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. Threshold cycle (Ct) values of the miR-
NAs were normalized in relation to that of U6. All assays were 
performed in triplicates, and one no-template control and two 
interplate controls were carried along in each experiment.
CT Diagnosis
Regular CT imaging was performed as part of clini-
cal standard care using a protocol with a 120-KV, 220-mA 
tomoscan (model Somatom Plus 4; Seimens, Munich, 
Germany). In brief, images were taken from the lung apices 
to the top of the kidneys at a speed of 1.0 seconds per rotation 
TABLE 2.  Demographic and Clinical Data of Lung Cancer Patients and Cancer-Free Controls in a Testing Set
Parameter Lung Cancer Patients % Cancer-Free Controls %
Total No. 64 73
Age, yr (SD) 66 (9) 64 (8)
Sex
  Men 41 64.1 48 65.8
  Women 23 35.9 25 34.2
Race
  White American 39 60.9 43 58.9
  African American 25 39.1 30 41.1
Smoking, pack-years (SD) 55 (16) 50 (17)
Nodule size (cm), median (SD) 2.7 (1.2) 1.2 (0.6)
Histology
  Adenocarcinoma 30 46.8
  Squamous-cell carcinoma 28 43.8
  Small-cell carcinoma 6 9.4
Stage of 58 NSCLC
  I 19 32.8
  II 19 32.8
  III–IV 20 34.4   
NSCLC, non–small-cell lung cancer.
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in helical motion. The slice thickness was 5 mm through the 
mediastinum (from the top of the aorta caudal to 2 cm below 
the bifurcation of the main stem bronchus) and 8 mm else-
where. One hundred milliliters of Optiray 240 (St. Louis, 
MO) was administered as the intravenous contrast agent at 
1.5 ml per second. The images were reconstructed by using 
the Kernal protocols of AB50 for the mediastinum and AB82 
Lo for the lung windows. The CT images were read indepen-
dently by two of five board-certified radiologists who were 
blinded to molecular analysis. The two radiologists’ findings 
were recorded and then discussed, and the consensus findings 
were documented for study purposes. When the two readers 
could not reach a consensus, the case was presented to another 
reader among the five, and the adjudicated reading became the 
final one. The diameter of a nodule, as a measure of its size, 
was defined as the average of its length and width measured 
with electronic calipers on the image that showed the largest 
cross-sectional area of the nodule. A positive result of initial 
CT was defined as previously described.31,32
Statistical Analysis
Pearson’s correlation coefficient tests with multivariate 
regression analysis were carried out to evaluate the associa-
tions between expressions of miRNAs and clinicopathologic 
and demographic characteristics of the participants. To deter-
mine the diagnostic performances of the miRNAs, receiver 
operating characteristics (ROC) curves were constructed by 
using expression levels for each miRNA in cancer patients and 
cancer-free controls.33 The cutoff value was chosen at the point 
of highest Youden index for each miRNA from the ROC in the 
training set. Furthermore, ROC plots were analyzed and areas 
under the curve (AUCs) were calculated. A logistic regression 
model with constrained parameters as in least absolute shrink-
age and selection operator was used to define an optimal panel 
of miRNAs that could differentiate lung cancer patients from 
controls with the highest sensitivity and specificity.34 To com-
pare the sensitivities and specificities of the panel of miRNAs 
and CT scan used alone, the combination of the miRNAs and 
CT, differences between AUC values of each approach were 
compared as described by Hanley and McNeil.35 All p values 
shown were two sided, and a p value less than 0.05 was con-
sidered statistically significant.
RESULTS
Demographic and Clinical 
Characteristics of the Subjects
Of the 66 lung cancer patients in the training set, 13 
patients had SCLC and 53 patients had NSCLC (Table 1). Of 
the 53 NSCLC cases, there were 17 NSCLC patients at stage 
I, 18 at stage II, and 18 at stage III–IV. There were 27 NSCLC 
patients with AC and 26 with SCC. The mean age of the lung 
cancer cases was 64 years and 37 were men. There were 38 
white and 28 African American patients diagnosed with lung 
cancer. The mean number of smoking pack-years of the lung 
cancer cases was 53. The 68 cancer-free subjects included 
39 with chronic obstructive pulmonary disease (COPD), 
16 with pneumonia, seven with sarcoidosis, and four with 
inflammatory granuloma. The cancer-free subjects comprised 
43 men. There were 48 whites and 20 African Americans. 
The mean age of the control subjects was 67 years. The mean 
number of smoking pack-years of the control subjects was 49. 
The mean size of SPNs in lung cancer patients and cancer-free 
smokers was 2.6 and 1.1 cm in diameter, respectively. In the 
testing set, six patients had SCLC and 58 had NSCLC. There 
were 19 NSCLC patients at stage I, 19 at stage II, and 20 at 
stage III–IV. There were 30 NSCLC patients with AC and 28 
with SCC. The mean age of the lung cancer cases was 66 years 
and 41 are men. There were 39 white and 25 African American 
patients diagnosed with lung cancer. The mean number of 
smoking pack-years of the lung cancer cases was 55. The 
73 cancer-free subjects comprised 40 with COPD, 18 with 
pneumonia, eight with sarcoidosis, and seven with inflamma-
tory granuloma. The cancer-free smokers comprised 48 men. 
There were 43 white and 30 African Americans. The mean 
age of the control subjects was 64 years. The mean number of 
smoking pack-years of the control subjects was 50. The mean 
size of SPNs in lung cancer patients and cancer-free smokers 
was 2.7 and 1.2 cm in diameter, respectively.
Expressions of the miRNAs in 
Sputum and the Correlations with 
Clinicopathological Characteristics
The 12 miRNAs were successfully tested in the sputum 
specimens of cases and controls by using qRT-PCR analysis 
with 32 Ct values or less. In the training set, 10 of the 12 
miRNAs (miRs-21, 31, 126, 182, 200b, 205, 210, 375, 486, 
and 708) displayed statistically different expression levels 
between cancer patients and controls by using Pearson’s cor-
relation coefficient test (all p < 0.01). miRs-21, 31, 182, 200b, 
205, 210, and 708 exhibited higher expression levels, whereas 
126, 375, and 486 displayed lower levels in sputum of lung 
cancer patients compared with the levels in cancer-free sub-
jects (all p < 0.01) (Supplementary Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A493). The 
expressions of the 10 miRNAs in sputum were related to the 
size of SPNs (all p < 0.01). The expression levels of miR-
31 and miR-486-5p in sputum were positively associated 
with smoking history of lung cancer patients (p = 0.04 and 
p < 0.01, respectively). The expressions of miRs-21, 200b, 
375, and 486 in sputum were more closely associated with AC 
(all p < 0.05), whereas miRs-205, 210, and 708 were related to 
SCC (All p < 0.05). There was no correlation of the changes 
of all the miRNAs with age, ethnicity, and lung tumor stage 
(All p > 0.05).
Optimizing a Panel of Sputum miRNA 
Biomarkers for Diagnosis of Lung Cancer
We used ROC curve analysis to evaluate capacity of each 
miRNA for discriminating lung cancer patients from controls 
in the training set. The individual miRNAs exhibited area 
under the ROC curve (AUC) values of 0.61 to 0.79 in distin-
guishing cancer cases from control subjects (Supplementary 
Table 1, Supplemental Digital Content 1, http://links.lww.
com/JTO/A493). Consequently, they yielded 53.1% to 76.0% 
sensitivities and 55.9% to 71.4% specificities for diagnosis 
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of lung cancer (Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A493). To optimize a 
panel of miRNA biomarkers for lung cancer with high accu-
racy, we used logistic regression models with constrained 
parameters as in least absolute shrinkage and selection opera-
tor to analyze the miRNAs. From the 10 miRNAs, miR-31 
and miR-210 were selected as the best biomarkers (all p < 
0.01). Combined use of the two miRNAs produced 0.83 AUC 
(Fig. 1), offering superior performance compared with any of 
the 10 miRNAs used alone (all p < 0.01). Furthermore, using 
all the 10 miRNAs together did not produce improvement of 
AUC value over the panel of the two miRNAs (all p > 0.05). 
The cutoff value for each of the two miRNAs was selected at 
the point of the highest Youden index. The use of the two miR-
NAs in combination generated 65.2% sensitivity and 89.7% 
specificity for lung cancer diagnosis. The maximum sensitiv-
ity for combined use of the two miRNA markers was 87.5% 
and the associated specificity was 59.6%. The two miRNAs 
did not exhibit statistical differences of sensitivity and speci-
ficity between stages and histologic subtypes of lung tumors (p 
> 0.05). Therefore, miR-31 and miR-210 used together might 
hold promise for diagnosis of the major types of lung cancer.
Comparison and Synergetic Value of 
the Sputum miRNA Biomarkers and 
CT for Lung Cancer Diagnosis
The initially regular CT scan identified 62 of the 66 lung 
cancer cases in the training set, and classified 11 of the 68 
cancer-free subjects as lung cancer patients, yielding 93.9% 
sensitivity and 83.8% specificity for diagnosis of lung can-
cer. Therefore, CT had a lower specificity, whereas a higher 
sensitivity than did the panel of the two miRNA biomarkers 
for lung cancer diagnosis (83.8% versus 89.7%; 93.9% versus 
65.2%, respectively; all p < 0.05).
To determine whether the panel of the miRNAs could 
improve CT, we incorporated the analysis of the miRNAs with 
CT diagnosis by using a logistic model. As displayed in Figure 
3, combined use of the miRNA biomarkers and CT generated 
0.95 AUC (Fig. 2A), which was significantly higher than that 
(0.83) of combined use of miR-31 and miR-210 (p < 0.05). 
Integrated analysis of the miRNAs and CT imaging had syner-
getic consequence. Subsequently, the combined strategy pro-
vided a considerably higher specificity (91.2% versus 83.8%; 
p < 0.05) and a similar sensitivity compared with CT (92.4% 
versus 93.9%; p > 0.05) (Fig. 2B). Therefore, integrated use of 
the miRNAs and CT scan would present a higher specificity 
compared with CT used alone, without significantly reduc-
ing its sensitivity for lung cancer diagnosis. Interestingly, the 
inclusion of pack-years of smoking history into this combined 
model further elevated the AUC from 0.95 to 0.97 (Fig. 3). 
Accordingly, a combined model with regular CT, smoking 
pack-years, and the miRNA biomarkers produced a higher 
specificity (95.6%) compared with CT imaging (83.8%), 
maintaining a similar sensitivity (95.5% versus 93.9%; p > 
0.05) for lung cancer diagnosis. Therefore, the sputum-based 
biomarkers might potentially be useful in increasing specific-
ity of CT scan for lung cancer diagnosis among smokers.
Validating the Diagnostic Performance of the 
Biomarker in the Testing Set of Specimens
To validate the panel of miRNA biomarkers for diag-
nosis of lung cancer, miR-31 and miR-210 were assessed 
on sputum of additional 64 stage I NSCLC patients and 73 
cancer-free smokers. In this testing set, miR-31 and miR-210 
displayed higher expression levels in sputum of lung cancer 
patients compared with cancer-free smokers (all p < 0.01). 
The individual miRNAs exhibited AUC values of 0.79 and 
0.77, respectively, in distinguishing cancer cases from con-
trol subjects (Supplementary Table 2, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A493). The expressions 
of the two miRNAs in sputum were positively related with 
smoking history and the size of SPNs of participants (all p 
< 0.01). There was no correlation of the changes of the two 
miRNAs with age, ethnicity, lung tumor stage, and histo-
logical types (all p > 0.05). Furthermore, the miRNAs used 
together differentiated lung cancer patients from the controls 
with 64.1% sensitivity and 89.2% specificity (Fig. 4) in the 
testing set, which were consistent with the parameters of the 
two miRNAs in the training set (65.2% sensitivity and 89.7% 
specificity). The observation might demonstrate the repeat-
ability of the potential sputum biomarkers for lung cancer. 
In addition, in the testing set of specimens, regular CT scan 
had 93.8% sensitivity and 83.6% specificity. Therefore, the 
miRNA biomarkers generated a higher specificity, whereas it 
showed a lower sensitivity compared with CT scan for lung 
cancer diagnosis (89.2% versus 83.6%; 64.1% versus 93.8%, 
respectively, all p < 0.05) (Fig. 4). Importantly, the incor-
poration of the miRNA biomarkers with CT diagnosis pro-
duced a significantly higher specificity (91.8% versus 83.6%; 
p < 0.05), and a similar sensitivity compared with CT (92.2% 
FIGURE 1.  miR-31 and miR-210 are identified as potential 
sputum biomarkers for diagnosis of lung cancer. Logistic 
regression models with constrained parameters as in least 
absolute shrinkage and selection operator based on area 
under ROC (AUC) are applied to optimize a small panel of 
miRNAs with high sensitivity and specificity from 10 miRNA 
candidates in a training set of 66 lung cancer patients and 68 
cancer-free smokers. Combined use of miR-31 and miR-210 
produces an AUC of 0.83. ROC, receiver operating character-
istics; AUC, area under the curve.
38 Copyright © 2013 by the International Association for the Study of Lung Cancer
Shen et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014
versus 93.8%; p > 0.05) (Fig. 4). Taken together, the results 
created from the testing set confirmed the robustness of analy-
sis of the sputum miRNAs, which could potentially augment 
CT’s specificity for lung cancer diagnosis.
DISCUSSION
The major challenge for the use of CT in clinical settings 
for lung cancer diagnosis is the lack of specificity commonly 
seen when it is applied to a population of heavy smokers. Our 
present research shows that a panel of miRNA might address 
the insufficiencies of CT, because the analysis of the miRNAs 
in sputum could increase CT’s specificity. Furthermore, the 
observation in the heterogeneous lung cancer cases indicates 
the potential of using the miRNAs for diagnosis of major 
subtypes of lung cancer, including AC, SCC, and SCLC. In 
addition, the miRNAs do not display difference between early 
and advanced stages of lung tumors. Moreover, the combined 
strategy of the miRNA biomarkers and CT not only overcomes 
the limitation of the radiological imaging that often produces 
a low specificity for lung cancer, but also surmounts the major 
obstacle of sputum-based biomarkers, by which, it is diffi-
cult to localize tumor masses in the lungs. Interestingly, the 
inclusion of smoking status into the combined model of the 
biomarkers and CT scan could dramatically increase the spec-
ificity of CT, while keeping a similar sensitivity. Therefore, 
FIGURE 3.  The inclusion of smoking factor into the com-
bined model of the miRNAs and CT improves the perfor-
mance of the model for lung cancer diagnosis in the training 
set of cases and controls. The addition of smoking pack-years 
to the miRNA biomarkers and CT has a high AUC value 
(0.97) compared with combined analysis of miRNAs and CT 
imaging for lung cancer diagnosis (0.95, p < 0.05). miRNAs, 
microRNAs; CT, computed tomography; AUC, area under the 
curve.
FIGURE 4.  The validation of the two miRNAs (miR-31 and 
miR-210) in a testing set of 64 lung cancer cases and 73 
cancer-free smokers confirms their performance in improv-
ing the specificity of CT scan for lung cancer diagnosis. 
Combined use of miR-31 and miR-210 could create 64.1% 
sensitivity and 89.2% specificity in the testing set. Regular CT 
scan produces 93.8% sensitivity and 83.6% specificity. CT 
has a lower specificity and a higher sensitivity compared with 
the panel of the miRNA biomarkers (all p < 0.05). Combined 
analysis of the miRNAs and CT imaging has a higher specific-
ity than does CT scan used alone (91.8% versus 83.6%;  
p < 0.05). miRNAs, microRNAs; CT, computed tomography.
FIGURE 2.  The panel of the two miRNAs (miR-31 and miR-210) improves the specificity of CT scan for lung cancer diagnosis 
in the training set of 66 cases and 68 cancer-free smokers. A, The incorporation of the two miRNAs with regular CT imaging 
creates 0.95 AUC, which is considerably higher than that (0.83) of the use of miR-31 and miR-210 in combination (p < 0.05).  
B, Combined use of miRs-31 and 210 can result in 65.2% sensitivity and 89.7% specificity. Initial CT scan produces 93.9% sensi-
tivity and 83.8% specificity. CT has a lower specificity and a higher sensitivity compared with the panel of the sputum miRNA 
biomarkers (all p < 0.05). Integrating the miRNAs and CT imaging yields a higher specificity than does CT scan used alone 
(91.2% versus 83.8%; p < 0.05). miRNAs, microRNAs; CT, computed tomography; AUC, area under the curve.
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the sputum-based miRNA biomarkers might potentially be 
useful in improving CT for diagnosis of lung cancer.
From our previously identified 12 lung tumor–associ-
ated miRNAs18,24–26 we previously showed that analysis of four 
miRNAs (miR-21, miR-486, miR-375, and miR-200b) could 
potentially be useful for diagnosis of AC, and three miRNAs 
(miR-205, miR-210, and miR-708) in sputum might be valu-
able to diagnose lung SCC.25,26 These previous observations 
are confirmed in the current study, because the expressions of 
miR-21, miR-486, miR-375, and miR-200b are more closely 
associated with AC, whereas the expression of miR-205, miR-
210, and miR-708 are more related to SCC. Furthermore, the 
results of the present study support our efforts in the develop-
ment of noninvasive biomarkers for lung cancer, as it optimizes 
a panel of two miRNA biomarkers (miR-31 and miR-210) that 
can augment CT scan for lung cancer, regardless of the dif-
ferent types. In addition, the repeatability of analysis of the 
biomarkers could be demonstrated by the fact that miRNAs 
display a similar sensitivity and specificity for diagnosis of 
lung cancer between training and testing sets. Therefore, the 
present study extends our previous work by further developing 
potential biomarkers that might diagnose major histological 
types of lung cancer. Given the heterogeneity of lung tumors, 
the panel of the two miRNA biomarkers would be more practi-
cally useful for diagnosing lung cancer, as compared with the 
ones25,26 that are only applied to a single type of lung cancer.
The two miRNAs (miR-31 and miR-210) that make up 
the potential biomarkers were suggested as being involved in 
tumorigenesis.36,37 Previously, miR-210 was found to regulate 
the hypoxic response of tumor cells.38–40 Its overexpression 
was detected in a variety of solid tumors.38,41,42 Furthermore, 
miR-210 overexpression associated with advanced stages 
of breast and oral cancers.43,44 Increased miR-210 expres-
sion could mediate mitochondrial changes associated with 
modulation of activity in lung cancer.45 In addition, analy-
sis of miR-210 expressions in serum could diagnose diffuse 
large B-cell lymphoma and pancreatic cancer.46,47 We recently 
showed that miR-210 was one of the miRNAs that could be 
measured in plasma for diagnosis of NSCLC.48 miR-31 might 
have a tissue-specific malignant role, because it has restricted 
expression patterns in carcinoma cells originating from differ-
ent tissues.34 A low expression level of miR-31 was found in 
primary breast tumors and inversely associated with the dis-
tant metastases.49 Up-regulation of miR-31 was observed in 
colorectal50 and head-and-neck tumors.51 Although the detail 
mechanism underlying miR-31 dysregulation in tumorigen-
esis remains to be investigated, studying miR-31 expression in 
serum could be a potential approach for diagnosis of esopha-
geal SCC.52
Sputum samples of some control subjects in the training 
and testing sets had altered miRNA expressions, which may 
be considered false positives. Intriguingly, all these cancer-
free subjects were either COPD patients or individuals hav-
ing more than 45 pack-year history of cigarette smoking. The 
data suggested that these lung cancer-related aberrant miRNA 
expressions might reflect chronic exposure to tobacco carcin-
ogens and chronic inflammatory conditions, such as COPD. 
Indeed, it is well known that smoking causes lung cancer 
and a fivefold increased risk of lung cancer among COPD 
patients.53–56 The abnormal miRNA expressions in sputum of 
the controls may be considered early events in the initiation 
of lung cancer, considering that the expressions of the miR-
NAs are associated with smoking history. Nevertheless, exten-
sive follow-up of the control subjects is needed to evaluate 
the possibility. Furthermore, our long-term goal is to develop 
a diagnostic assay that could improve CT to screen smokers 
for lung cancer. As a first step, this current study is to use a 
retrospective cohort to develop potential biomarkers for lung 
cancer. To finally achieve our long-term goal, we are perform-
ing a prospective study to evaluate the prediction performance 
of the biomarkers in asymptomatic heavy smokers for early 
detection of lung cancer.
In conclusion, we identified a panel of miRNAs in spu-
tum that might be potential biomarkers for lung cancer, cov-
ering major histological types. The sputum-based biomarkers 
could augment CT scan, and particularly improve its specific-
ity for diagnosis of lung cancer in smokers. We are under-
taking a large population study to extensively and vigorously 
evaluate the usefulness of the biomarkers for the early detec-
tion of lung cancer in smokers, which is crucial to translate 
the newly discovered biomarkers to clinical settings.57 If suc-
cessful, the future use of sputum-based miRNA biomarkers 
with radiological imaging would improve the ability to detect 
lung cancer in smokers at its early stage where therapeutic 
interventions have a curative potential.
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